<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813551</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-0198</org_study_id>
    <nct_id>NCT02813551</nct_id>
  </id_info>
  <brief_title>ToRsemide for pOstpartum HYpertension</brief_title>
  <acronym>TROPHY</acronym>
  <official_title>Torsemide for the Prevention of Persistent Postpartum Hypertension in Preeclamptic Women: A Randomized, Placebo-Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently there is no intervention to prevent persistent postpartum hypertension in
      preeclamptic women. Physiologically, the use of a pharmacokinetically predictable
      loop-diuretic is a reasonable intervention to increase elimination of extra fluid accumulated
      secondary to preeclampsia.The purpose of this study is to assess if Torsemide reduces the
      incidence of persistent postpartum hypertension in preeclamptic women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">September 9, 2017</completion_date>
  <primary_completion_date type="Actual">July 28, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg</measure>
    <time_frame>0-5 days after delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of severe postpartum hypertension</measure>
    <time_frame>0-6 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for postpartum readmission</measure>
    <time_frame>0-6 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay after delivery</measure>
    <time_frame>0-5 days after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>0-5 days after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lower extremity edema</measure>
    <time_frame>0-5 days after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent postpartum hypertension</measure>
    <time_frame>0-6 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of therapy: hypokalemia</measure>
    <time_frame>0-5 days after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of therapy: failure to establish lactation</measure>
    <time_frame>0-5 days after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe composite maternal morbidity</measure>
    <time_frame>0-6 weeks after delivery</time_frame>
    <description>Any of the following: ICU admission, HELLP syndrome, eclampsia, stroke, renal failure, pulmonary edema, cardiomyopathy or maternal death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Torsemide concentrations in breast milk</measure>
    <time_frame>0-5 days after delivery</time_frame>
    <description>Ancillary study</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrolyte profile in maternal serum</measure>
    <time_frame>0-5 days after delivery</time_frame>
    <description>Concentrations of: Sodium, Potassium, Calcium</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Torsemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Torsemide 20 mg daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 20 mg daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torsemide</intervention_name>
    <arm_group_label>Torsemide</arm_group_label>
    <other_name>Demadex, torasemide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postpartum women at ≥ 18 years of age

          -  Antepartum/intrapartum or within 24 hours postpartum diagnosis of either:

          -  Preeclampsia

          -  Preeclampsia with severe features

          -  Preeclampsia superimposed to chronic hypertension

        Exclusion Criteria:

          -  Chronic hypertension without superimposed preeclampsia

          -  Gestational hypertension

          -  Urine output &lt; 30 cc/h at time of randomization

          -  Heart failure or pulmonary edema

          -  Hypersensitivity to Torsemide or sulfonylureas

          -  Hypokalemia (serum potassium &lt; 3 mEq/L)

          -  Preexisting diuretic use within 24 hours prior to randomization
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Oscar Andres Viteri Molina</investigator_full_name>
    <investigator_title>Maternal-Fetal Medicine Fellow</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia, puerperium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torsemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

